Ion Suehiro
University of California, San Francisco
4 Papers
Ion Suehiro is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Omecamtiv mecarbil & Myosin. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Fady I. Malik,James J. Hartman,Kathleen A. Elias,Bradley P. Morgan,Hector P. Rodriguez,Katjuša Brejc,Robert L. Anderson,Sandra H. Sueoka,Kenneth Lee,Jeffrey T. Finer,Roman Sakowicz,Ramesh Baliga,David R. Cox,Marc Garard,Guillermo Godinez,Raja Kawas,Erica Kraynack,David Lenzi,Pu Ping Lu,Alexander Muci,Congrong Niu,Xiangping Qian,Daniel W. Pierce,Maria Pokrovskii,Ion Suehiro,Sheila Sylvester,Todd Tochimoto,Corey Valdez,Wenyue Wang,Tatsuo Katori,David A. Kass,You Tang Shen,Stephen F. Vatner,David J. Morgans +33 more
TL;DR: It is shown that omecamtiv mecarbil binds to the myosin catalytic domain and operates by an allosteric mechanism to increase the transition rate of myOSin into the strongly actin-bound force-generating state.
Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator
Scott Collibee,Gustave Bergnes,Alexander Muci,William F. Browne,Marc Garard,Aaron C. Hinken,Alan J. Russell,Ion Suehiro,James J. Hartman,Raja Kawas,Pu-Ping Lu,Kenneth Lee,David Marquez,Matthew Tomlinson,Donghong Xu,A Kennedy,Darren Hwee,Julia Schaletzky,Kwan Leung,Fady I. Malik,David J. Morgans,Bradley P Morgan +21 more
TL;DR: The identification and optimization of the first activators of fast skeletal muscle are reported and Optimization of 1 for potency, metabolic stability, and physical properties led to the discovery of tirasemtiv, which has been extensively characterized in clinical trials for the treatment of amyotrophic lateral sclerosis.
29
Successful treatment of ventriculostomy-associated meningitis caused by multidrug resistant coagulase-negative Staphylococcus epidermidis using low-volume intrathecal daptomycin and loading strategy.
TL;DR: It was reported successful use of low-volume intrathecal daptomycin and loading strategy for the treatment of ventriculostomy-associated meningitis without adverse sequelae and the patient was discharged on hospital day 50 without antibiotics.
Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin
Bradley P. Morgan,Alexander Muci,Pu-Ping Lu,Xiangping Qian,Todd Tochimoto,Smith Whitney W,Marc Garard,Erica Kraynack,Scott Collibee,Ion Suehiro,Adam Lewis Tomasi,S. Corey Valdez,Wenyue Wang,Hong Jiang,James J. Hartman,Hector M. Rodriguez,Raja Kawas,Sheila Sylvester,Kathleen A. Elias,Guillermo Godinez,Kenneth Lee,Robert F. Anderson,Sandra H. Sueoka,Donghong Xu,Zhengping Wang,Nebojsa Djordjevic,Fady I. Malik,David J. Morgans +27 more
TL;DR: The design, synthesis, and optimization of the first, selective activators of cardiac myosin activators are reported, currently in clinical trials for the treatment of systolic heart failure.